Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882791 · ClinicalTrials.gov registry record
Basal Cell Carcinoma Recurrence After Mohs Surgery
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 115
- Enrollment target
NCT00882791: Completed study, sponsored by Northwestern University.
NCT00882791 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00882791 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement. Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
What the finished NCT00882791 record still lists
NCT00882791 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00882791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00882791 about?
NCT00882791 is a clinical study titled "Basal Cell Carcinoma Recurrence After Mohs Surgery". Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surger...
What is the current status of trial NCT00882791?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2008-05. Estimated completion is 2009-05.
Who is sponsoring clinical trial NCT00882791?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia